Global Fund raises $14 billion to fight AIDS, tuberculosis and malaria

11 October 2019

Donors at the Global Fund's sixth annual conference have pledged a record-breaking $14 billion for the next three years – the largest amount ever raised for an organization of this kind.

Set up to accelerate research aimed at ending epidemics of AIDS, tuberculosis and malaria, the Global Fund is a partnership between governments, civil society, the private sector and people affected by the diseases.

Speaking at the conference, French President Emmanuel Macron called on all partners to increase their commitments by at least 15% in order to reach the target.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK